Ark Biosciences discovers and develops small‑molecule, antibody, and Fc‑conjugate therapeutics for unmet respiratory, fibrotic, and pediatric neurodevelopmental diseases such as RSV, IPF, COPD, and ADHD. Leveraging proprietary platforms and global partnerships, the company advances first‑in‑class or best‑in‑class candidates—including oral RSV inhibitors, monoclonal antibodies, anti‑fibrotic agents, and long‑acting antiviral conjugates—through pre‑clinical and clinical stages to provide safer, more effective treatment options.
Funding
Funding not disclosed
4OLVFounders
Product
Problem
Patients with respiratory and pediatric diseases such as RSV infection, idiopathic pulmonary fibrosis, COPD, ADHD, and influenza have limited therapeutic options, with many existing drugs showing poor efficacy, safety concerns, or no approved treatments at all.
Solution
Ark Biosciences focuses on discovering and developing innovative small‑molecule, antibody, and Fc‑conjugate therapeutics that address these unmet medical needs. The company leverages proprietary platforms to create first‑in‑class or best‑in‑class agents with novel mechanisms, such as RSV fusion‑protein inhibition (AK0529), RSV‑preventive monoclonal antibodies (AK0610), anti‑fibrotic small molecules (AK3280), long‑acting antiviral Fc‑conjugates for influenza (AK0406), and targeted ADHD formulations (AK0901). Its pipeline spans pre‑clinical, IND‑enabling, and late‑stage clinical phases, supported by global collaborations with academic institutions and multinational pharma partners. By advancing candidates through rigorous clinical trials and securing regulatory designations, Ark aims to bring safer, more effective treatments to patients worldwide.
Target Audience
Primary customers are pharmaceutical partners, clinical investigators, and healthcare providers seeking advanced therapies for respiratory, fibrotic, and pediatric neurodevelopmental disorders.
Features
- AK0529 (ziresovir): oral RSV fusion‑protein inhibitor with breakthrough‑therapy designation and positive Phase III data.
- AK0610: fully human monoclonal antibody targeting the RSV pre‑fusion F protein, designed for long‑lasting prophylaxis in infants.
- AK3280: next‑generation anti‑fibrotic agent derived from the pirfenidone scaffold, showing improved safety and efficacy in IPF trials.
- AK0406: Fc‑conjugated antiviral drug delivering broad‑spectrum, long‑acting influenza protection; currently in Phase I in Australia.
- AK0901 (Azstarys): methylphenidate‑based ADHD therapy with novel delivery, approved in the U.S. and in Phase III in China.
- AK0705: reversible covalent neutrophil inhibitor targeting inflammatory pathways in COPD, in IND‑enabling development.
- Integrated global R&D network combining internal discovery platforms with external partnerships (e.g., Roche, Scripps, Chinese Academy of Sciences).
- Robust clinical development infrastructure covering IND filing, multi‑regional Phase I‑III trials, and regulatory submissions (FDA, NMPA, WHO).